# Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.

> **NCT05181462** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Cantargia AB** · enrollment: 117 (actual)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Gemcitabine
- **DRUG:** Nadunolimab

## Key facts

- **NCT ID:** NCT05181462
- **Lead sponsor:** Cantargia AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-01-11
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-08
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05181462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05181462, "Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT05181462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*